research
focus
develop
specif
assay
conclus
identifi
measur
level
bacteria
fungi
protozoa
virus
microb
associ
product
biomark
caus
diseas
human
anim
murray
et
al
tradit
method
use
microscopi
chemic
immunolog
stain
test
cultur
select
media
target
cell
serolog
assay
use
effect
identifi
infecti
agent
biolog
specimen
environment
sampl
howev
due
increas
veterinari
medic
public
health
concern
faster
accur
diagnost
tool
sought
multiplex
arraybas
assay
allow
rang
biomark
rapidli
simultan
measur
within
specimen
robertson
nicholson
recent
multiplex
beadbas
flow
cytometr
immunoassay
develop
appli
show
great
promis
improv
studi
diagnosi
therapeut
manag
infecti
diseas
alvarezbarriento
et
al
jani
et
al
advent
genet
molecular
engin
monoclon
antibodi
gener
driven
develop
mani
assay
employ
immunoassaybas
technolog
specif
measur
variou
biomark
highli
purifi
recombin
synthet
molecul
use
antigen
gener
specif
antibodi
prepar
provid
target
antigen
calibr
standard
assay
radioimmunoassay
ria
enzymelink
immunosorb
assay
elisa
wide
use
specif
sensit
analyt
measur
diagnost
valu
andreotti
et
al
although
methodolog
well
suit
singleanalyt
analysi
rel
larg
sampl
volum
method
simultan
quantit
multipl
analyt
rel
small
sampl
size
need
improv
speed
util
confid
diagnost
assay
combin
tradit
immunoassaybas
technolog
multiparamet
flow
cytometri
promot
develop
beadbas
highthroughput
multiplex
immunoassay
method
polym
microspher
bead
sever
micromet
diamet
replac
tradit
immunoassay
plate
serv
solid
phase
flow
cytometr
assay
horan
wheeless
mani
differ
type
beadbas
flow
cytometr
immunoassay
describ
includ
indirect
sandwich
immunoassay
format
mchugh
et
al
vignali
indirect
immunoassay
format
especi
use
measur
specif
antibodi
level
biolog
fluid
eg
determin
rise
fall
serum
antibodi
titer
cours
infecti
diseas
format
captur
bead
coat
coval
conjug
target
antigen
molecul
fig
diagnost
microbiolog
assay
may
either
crude
microbi
extract
highli
purifi
molecular
prepar
bead
mix
test
biolog
fluid
tissu
cultur
supernat
serum
wound
exud
bronchial
lavag
fluid
may
contain
specif
antibodi
solut
sampl
contain
quantifi
level
antibodi
specif
analyt
interest
serv
assay
calibr
standard
ad
fluoresc
antiimmunoglobulin
detect
antibodi
dab
develop
assay
fluoresc
dab
may
specif
immunoglobulin
isotyp
assay
total
antibodi
level
measur
altern
dab
may
specif
immunoglobulin
isotyp
thu
allow
measur
antibodi
igm
iga
igg
ige
isotyp
isotypespecif
measur
antibodi
level
may
import
monitor
cours
infecti
diseas
character
natur
immun
respons
vaccin
wild
level
isotyp
profil
antibodi
may
indic
whether
humor
immun
respons
weakli
strongli
protect
nonprotect
particular
infecti
diseas
sandwich
immunoassay
format
specif
captur
antibodi
noncoval
adsorb
coval
bound
plastic
bead
fig
captur
bead
mix
biolog
fluid
contain
target
analyt
interest
eg
solubl
microbi
antigen
includ
structur
molecul
enzym
toxin
incub
captur
bead
sampl
fluoresc
dab
biotinyl
dab
develop
fluoresc
avidin
conjug
ad
serv
report
fluorophor
analyt
level
beadbas
flow
cytometr
immunoassay
proport
mean
fluoresc
intens
mfi
level
gener
beadanalytebound
fluoresc
dab
inclus
standard
antigen
known
concentr
natur
synthes
recombin
molecul
standard
dilut
curv
gener
correspond
level
target
analyt
interpol
beadbas
singl
analyt
flow
immunoassay
first
describ
measur
level
frengen
et
al
bishop
davi
multiplex
beadbas
flow
cytometr
immunoassay
made
possibl
use
bead
differ
size
mchugh
fulwyl
et
al
use
bead
differ
size
carrier
target
antigen
antibodi
bead
differenti
size
relat
forward
lightscatt
characterist
determin
flow
cytometr
analysi
appropri
electron
gate
strategi
use
data
acquisit
c
bead
emit
fluoresc
signal
distinguish
term
wavelength
depend
type
dye
fluoresc
intens
depend
incorpor
dye
level
panel
b
altern
flow
cytometr
sandwich
immunoassay
dy
bead
conjug
specif
captur
antibodi
cab
mix
specimen
standard
solut
captur
bead
specif
bind
local
antigen
surfac
fluoresc
detect
antibodi
dab
ad
bind
anoth
antigen
site
panel
c
larg
number
differ
bead
posit
resolv
twocolor
dot
plot
exampl
logarithm
amplifi
channel
bd
facscalibur
flow
cytomet
nir
red
channel
bd
facsarray
bioanalyz
differ
bead
set
bead
differ
twocolor
fluoresc
posit
combin
assay
creat
multiplex
assay
incid
light
caus
fluoresc
dab
directli
conjug
fluorochrom
phycoerythrin
pe
emit
distinct
fluoresc
signal
report
signal
intens
commensur
amount
analytebound
dab
connect
distinct
fluoresc
captur
bead
set
flow
cytometr
data
reanalyz
gener
standard
curv
quantifi
level
specif
analyt
test
specimen
panel
standard
curv
gener
cytokin
cba
flex
set
analysi
shown
reanalysi
determin
mean
fluoresc
intens
emit
fluoresc
dab
associ
distinct
captur
bead
group
multiplex
flow
cytometr
immunoassay
also
made
use
bead
size
uniqu
fluoresc
properti
assay
distinct
captur
bead
set
produc
label
differ
level
one
type
fluoresc
dye
differ
captur
bead
set
distinguish
flow
cytometr
analysi
base
distinct
mfi
fluoresc
dab
provid
second
type
fluoresc
constitut
report
immunoassay
signal
camilla
et
al
approach
use
creat
lowcomplex
beadset
chen
et
al
howev
larger
distinguish
bead
set
prepar
label
distinct
proport
two
fluoresc
dye
fulwyl
et
al
exampl
red
far
dye
detect
flow
cytomet
fig
case
dab
coupl
third
fluoresc
dye
eg
phycoerythrin
pe
gener
immunoassay
signal
approach
possibl
develop
number
differ
captur
beaddab
pair
pair
initi
develop
test
separ
sensit
rang
analyt
measur
part
valid
process
pair
mix
togeth
bead
pair
test
capac
specif
measur
analyt
mixtur
serum
sampl
cocktail
dilut
standard
captur
beaddab
pair
must
capabl
specif
measur
analyt
level
test
separ
mixtur
select
good
antibodi
pair
crossreact
analyt
antibodi
system
flow
cytometr
immunoassay
use
measur
level
multipl
analyt
eg
biolog
marker
associ
one
microorgan
beadcaptur
analyt
level
measur
multiplex
flow
cytometr
immunoassay
proport
mean
fluoresc
intens
level
gener
beadanalytebound
fluoresc
dab
inclus
calibr
analyt
solut
eg
solut
contain
target
antigen
antibodi
known
concentr
standard
dilut
curv
gener
correspond
level
target
analyt
interpol
data
reanalysi
use
immunoassay
softwar
provid
select
varieti
standard
curvefit
choic
allow
best
fit
immunoassay
signal
function
standard
sampl
concentr
may
includ
either
linearlog
loglog
fouror
fiveparamet
transform
fig
multiplex
flow
cytometr
immunoassay
ideal
measur
biomark
associ
multipl
infecti
agent
jani
et
al
may
particularli
import
complex
diseas
gener
acquir
immunodefici
caus
human
immunodefici
viru
hiv
immunodefici
individu
suscept
infect
caus
multipl
opportunist
pathogen
altern
multipl
biomark
associ
particular
infecti
agent
analyz
conclus
diagnosi
prognosi
latter
case
biomark
incub
acut
convalesc
recoveri
phase
diseas
caus
infecti
agent
care
monitor
multiplex
flow
cytometr
immunoassay
simplifi
analyt
profil
determin
singl
sampl
need
detect
quantifi
number
analyt
advantag
sampl
volum
limit
eg
pediatr
cerebrospin
fluid
sampl
multipl
independ
measur
within
bead
popul
assur
good
precis
high
sensit
wide
detect
rang
afford
logarithm
amplifi
fluoresc
signal
highresolut
digit
data
system
anoth
advantag
eg
fewer
sampl
dilut
requir
moreov
greater
surfac
area
exposur
solubl
analyt
improv
beadbas
assay
kinet
compar
tradit
microwel
platebas
immunoassay
follow
section
exampl
multiplex
beadbas
flow
cytometr
immunoassay
appli
diagnost
microbiolog
present
includ
method
measur
level
specif
antibodi
gener
host
specif
microbi
pathogen
well
detect
microbi
pathogen
effector
molecul
addit
potenti
use
multiplex
assay
measur
biolog
respons
modifi
cytokin
chemokin
produc
consequ
infect
lead
diseas
state
instanc
present
flow
cytometr
immunoassay
well
suit
monitor
antibodi
respons
antigen
infecti
agent
determin
stabl
rise
drop
antibodi
titer
immunoglobulin
isotyp
antimicrobi
antibodi
provid
valuabl
inform
concern
natur
statu
infect
efficaci
antimicrobi
therapi
vaccin
grow
list
public
technolog
report
jani
et
al
best
colleagu
success
develop
indirect
bead
assay
serodiagnosi
helicobact
pylori
assay
investig
coat
plastic
microspher
crude
multicompon
antigen
mixtur
prepar
h
pylori
react
antibodi
present
patient
sera
fluoresceinconjug
antihuman
igg
dab
use
measur
level
igg
antih
pylori
antibodi
present
serum
sampl
infect
posit
cultur
histolog
examin
noninfect
control
patient
pool
neg
sera
serv
determin
assay
limit
detect
rel
serum
antibodi
titer
weakli
strongli
posit
control
sera
includ
assay
control
intraand
interassay
variabl
beadbas
assay
sensit
specif
posit
neg
predict
valu
gave
equivoc
result
parallel
test
commerci
elisa
sensit
specif
posit
neg
predict
valu
gave
five
equivoc
result
lal
et
al
develop
simpl
rapid
cytometr
bead
assay
simultan
quantit
serum
igg
antibodi
direct
neisseria
meningitidi
serogroup
c
differ
bead
set
conjug
meningococc
capsular
polysaccharid
c
calibr
antimeningococc
antiserum
serv
refer
tetraplex
assay
good
intraand
interassay
variat
show
strong
correl
elisa
specif
antigen
author
suggest
assay
type
would
use
studi
efficaci
multival
vaccin
design
protect
meningococc
infect
biagini
et
al
similarli
report
develop
multiplex
beadbas
assay
capabl
measur
antibodi
respons
direct
pneumococc
capsular
polysaccharid
pneumococc
polysaccharid
serotyp
present
pneumococc
polysaccharid
vaccin
licens
us
food
drug
administr
indirect
multiplex
flow
cytometr
immunoassay
also
report
quantit
specif
igg
antibodi
level
peconjug
antihuman
igg
direct
haemophilu
influenza
type
b
polysaccharid
toxoid
clostridium
tetani
corynebacterium
diphtheria
picker
et
al
investig
use
pool
serum
standard
calibr
standard
antisera
world
health
organ
unitsml
us
food
drug
administr
antibodi
quantit
antibodi
level
measur
preand
postvaccin
antisera
flow
cytometr
immunoassay
agre
close
determin
individu
elisa
use
type
assay
evalu
vaccin
efficaci
demonstr
mchugh
et
al
produc
cytometr
bead
assay
detect
quantit
serum
antibodi
direct
hepat
c
viru
hcv
microspher
differ
size
coat
protein
either
viral
core
nonstructur
region
bead
incub
serum
plasma
sampl
develop
peconjug
antihuman
igg
dab
assay
mixtur
analyz
multiparamet
flow
cytometr
analysi
forward
lightscatt
characterist
bead
use
identifi
smaller
hcv
core
larger
bead
associ
immunofluoresc
pe
signal
assay
develop
mchugh
colleagu
sensit
commerci
elisa
could
resolv
indetermin
clinic
sampl
type
assay
great
potenti
screen
donor
blood
sampl
multiplex
flow
cytometr
immunoassay
also
develop
identifi
microb
present
specimen
park
et
al
creat
competit
inhibit
multiplex
flow
cytometr
immunoassay
simultan
identifi
streptococcu
pneumonia
serotyp
latex
bead
set
differ
size
incorpor
level
red
fluoresc
dye
coat
differ
pneumococc
capsular
polysaccharid
brief
bead
mix
individu
pneumococc
lysat
follow
addit
pool
rabbit
antisera
serotyp
plu
fluoresceinconjug
antirabbit
immunoglobulin
dab
upon
flow
cytometr
analysi
fluoresc
dab
signal
inhibit
homolog
serotyp
pneumococcu
present
method
capabl
correctli
identifi
pneumococc
isol
test
molecular
biolog
techniqu
also
compat
beadbas
flow
cytometr
assay
differ
pcr
amplif
strategi
use
demonstr
flow
method
measur
hiv
viral
load
mehrpouyan
et
al
van
cleve
et
al
defoort
develop
multiplex
flow
cytometr
beadbas
hybrid
assay
detect
human
immunodefici
viru
type
hepat
c
hcv
rna
hepat
b
viru
hbv
dna
use
specif
oligonucleotid
probeco
green
fluoresc
microspher
assay
devoid
crosshybrid
oligonucleotid
probe
biotinyl
pcr
product
gener
multiplex
revers
transcriptionpcr
bound
pcr
product
detect
pecyanin
streptavidin
method
type
extrem
use
detect
quantit
sever
differ
pathogen
serotyp
plasma
sampl
flow
cytometr
assay
base
nucleic
acid
technolog
use
identifi
pathogen
amen
cultur
immunodomin
microbi
antigen
serv
serolog
diagnosi
ongo
infect
character
requir
highli
train
technician
expens
equip
materi
concern
nucleic
acid
technolog
discrimin
viabl
dead
microb
potenti
issu
affect
use
method
novel
method
simultan
measur
level
specif
microb
product
complex
specimen
also
possibl
exampl
cytometr
bacteria
protein
assay
cbpa
develop
bolton
et
al
sandwich
flow
cytometr
immunoassay
compon
cbpa
antibodi
gener
staphylococcu
aureu
enterotoxin
b
seb
ricin
antibodi
use
prepar
two
distinct
set
singlecolor
fluoresc
captur
bead
peconjug
dab
purifi
prepar
seb
ricin
communi
agglutinin
ii
serv
calibr
case
identif
bacteria
use
capabl
flow
cytomet
detect
bacteria
directli
light
scatter
dyemedi
nucleic
acid
fluoresc
specif
identif
achiev
fluorochromelabel
speciesspecif
antibodi
use
membran
permeabl
imperm
nucleic
acid
dye
allow
discrimin
live
dead
cell
simultan
analysi
kill
bacillu
anthraci
live
bacillu
subtili
bacteria
rabbit
antib
anthraci
antibodi
conjug
pe
discrimin
total
dead
bacteria
nucleic
acid
dye
syto
propidium
iodid
use
respect
perform
cbpa
known
amount
toxin
bacteria
captur
bead
mix
togeth
assay
diluent
along
peconjug
antiseb
b
trucount
bead
antiricin
antib
anthraci
antibodi
mixtur
serial
dilut
ad
trucount
tube
bd
bioscienc
san
jose
ca
min
room
temperatur
tube
contain
known
number
fluoresc
microspher
enabl
flow
cytometr
enumer
bacteria
alsharif
godfrey
pi
ad
min
follow
addit
millard
et
al
mixtur
analyz
multicolor
flow
cytometri
facsort
bd
bioscienc
cytomet
equip
blue
nm
red
laser
gener
multiparamet
fluoresc
forwardand
sidelight
scatter
signal
dot
plot
shown
figur
panel
b
reveal
cbpa
capac
simultan
discrimin
beadbas
measur
seb
ricin
toxin
level
viabl
b
subtili
nonviabl
b
anthraci
figur
panel
show
dot
plot
analysi
vs
singl
tube
assay
contain
two
bacteria
b
anthraci
b
subtili
stain
pi
dye
two
differ
intens
fluoresc
bead
popul
coupl
captur
antibodi
specif
seb
ricin
toxin
panel
b
show
result
assay
ad
antiseb
antiricin
pe
label
detector
antibodi
caus
increas
fluoresc
shift
bead
right
trucount
bead
ad
aid
bacteri
quantit
standard
curv
serial
dilut
toxin
panel
b
subtili
count
panel
b
shown
fig
bacteri
concentr
calcul
ratio
count
bacteria
trucount
microspher
numer
investig
oliv
et
al
chen
et
al
describ
multiplex
method
measur
panel
secret
cytokin
serum
exampl
carson
vignali
demonstr
multiplex
bead
assay
simultan
quantit
cytokin
multiplex
measur
cytokin
profil
flow
cytometr
bead
array
panel
may
use
monitor
host
respons
variou
infecti
diseas
process
infect
sepsi
frequent
caus
neonat
morbid
mortal
tarnok
et
al
earli
diagnosi
diseas
process
difficult
clinic
sign
highli
variabl
subtl
similar
condit
advanc
diagnost
detect
pediatr
infect
sepsi
slow
recent
advanc
multiplex
cytometr
bead
array
analysi
multipl
cytokin
show
promis
improv
earli
diagnos
elev
level
serum
among
propos
earli
indic
infect
sepsi
hodg
et
al
measur
serum
level
inflammatori
cytokin
biomark
follow
cours
pediatr
sepsi
case
investig
use
bd
cba
human
cytokin
measur
level
human
inflammatori
cytokin
kit
simultan
measur
multipl
cytokin
smallvolum
ml
sampl
assay
chosen
diagnost
potenti
associ
rise
plasmaderiv
cytokin
level
pediatr
sepsi
cytokin
group
infect
term
neonat
cultur
posit
noninfect
control
group
cultur
neg
analyz
cytokin
level
infect
group
compar
normal
rang
plasma
cytokin
level
express
control
group
two
patient
fail
show
signific
elev
cytokin
test
patient
show
elev
level
one
nine
cytokin
test
although
differ
cytokin
profil
correl
ident
specif
infecti
agent
author
conclud
type
assay
could
develop
rapidli
identifi
neonat
sepsi
multiplex
bead
assay
becom
valuabl
biolog
tool
due
abil
measur
multipl
protein
simultan
laboratori
sampl
speed
accuraci
specif
given
technolog
adapt
measur
cytokin
chemokin
immun
mediat
small
volum
sera
plasma
role
multiplex
bead
assay
profil
immun
pathogenesi
host
immun
respons
involv
human
diseas
recent
emerg
sever
acut
respiratori
syndrom
sar
highli
contagi
respiratori
diseas
caus
newli
identifi
sar
coronaviru
sar
cov
emerg
late
guangdong
provinc
china
cdc
updat
peiri
et
al
skowronski
et
al
sar
infect
person
worldwid
date
kill
patient
infect
sar
suffer
fever
cough
muscl
ach
short
breath
often
progress
sever
lung
inflamm
patient
recov
ill
within
week
howev
larg
percentag
sar
patient
develop
sever
complic
although
sar
outbreak
larg
contain
public
health
measur
clear
futur
threat
similar
emerg
virus
microbi
agent
caus
sever
respiratori
diseas
easili
elimin
sar
cov
infect
appear
hallmark
poorli
defin
cytokin
storm
lung
circulatori
system
sar
patient
huang
et
al
current
sar
immunolog
literatur
base
one
cytokin
make
unclear
immun
respons
progress
lung
injuri
culmin
poor
outcom
contrast
one
might
expect
immun
system
face
common
microbi
invad
may
infect
lung
injuri
progress
sar
patient
result
uncontrol
innat
adapt
immun
respons
reflect
rampant
lung
inflamm
uncoordin
cytokin
product
vari
sever
sar
cov
infect
appear
root
patient
host
immun
respons
sar
repres
uniqu
opportun
look
pathogenesi
critic
infecti
diseas
host
defens
new
light
use
multiplex
bead
assay
bd
bioscienc
cytometr
bead
array
cba
kit
public
health
direct
associ
toronto
sar
outbreak
spring
requir
individu
contact
sarsinfect
patient
develop
sar
symptom
present
hospit
assess
treatment
close
surveil
direct
like
common
featur
futur
outbreak
emerg
unknown
infecti
diseas
allow
collect
specimen
within
day
onset
symptom
acut
ill
sar
patient
well
longitudin
studi
patient
delin
sever
sar
diseas
cours
ie
mild
moder
symptom
sever
form
diseas
requir
intub
icu
admitt
cba
result
repres
nonicu
patient
shown
fig
show
high
level
proinflammatori
cytokin
chemokin
plasma
sar
patient
earli
phase
day
sinc
onset
symptom
diseas
compar
convalesc
sampl
averag
healthi
control
level
shown
earli
sar
infect
character
increas
express
numer
cytokin
chemokin
repres
vigor
acutephas
respons
well
strong
innat
adapt
immun
respons
level
express
cytokin
chemokin
appear
peak
within
first
week
sar
diseas
gener
resolv
healthi
control
level
convalesc
probabl
assist
aggress
steroid
treatment
begun
day
patient
elev
level
measur
onset
symptom
major
sar
patient
would
suggest
earli
skew
sar
immun
favor
helper
th
respons
vigor
earli
innat
immun
respons
may
critic
piec
puzzl
interferonrespons
gene
crucial
start
direct
differ
class
innat
adapt
immun
respons
would
indic
also
could
determin
overal
effect
convers
overal
mismanag
immun
respons
sar
cov
interestingli
cytokin
involv
adapt
immun
cell
subset
regul
express
signific
level
although
level
increas
slightli
second
week
ill
word
describ
sar
mediat
gener
cytokin
storm
probabl
oversimplifi
instead
bd
bioscienc
cba
accord
manufactur
instruct
higher
level
observ
sar
patient
rel
control
p
also
significantli
lower
day
mild
moder
sar
patient
compar
icu
p
immunolog
sar
appear
driven
time
select
subset
cytokin
chemokin
caus
unab
innat
adapt
immun
respons
respons
viru
one
chemokin
produc
unusu
high
level
earli
sar
infect
interferon
ifn
induc
protein
show
elev
level
sar
case
earli
onset
fig
sar
patient
mild
moder
symptom
level
decreas
near
convalesc
level
mid
stage
day
wherea
level
sar
patient
sever
symptom
requir
intub
admitt
icu
remain
significantli
elev
beyond
day
regardless
aggress
steroid
treatment
yet
known
whether
infect
tissu
main
sourc
although
persist
elev
level
patient
sever
ill
unresolv
sar
cov
infect
indic
may
case
nonetheless
appear
play
uniqu
role
progress
sar
ill
chemokin
known
role
cell
recruit
also
activ
immun
cell
shape
immun
respons
luster
rossi
zlotnik
although
interferon
interferonrespons
gene
ie
may
play
gener
role
modul
respiratori
diseas
involv
lung
injuri
appear
play
special
dual
role
sar
interferon
respons
necessari
clear
sar
cov
properli
time
modul
minor
patient
particip
pathogenesi
sar
poor
outcom
uncontrol
inflamm
continu
recruit
activ
cell
mononuclear
infiltr
inde
control
outcom
coronaviru
infect
mous
model
diseas
liu
et
al
liu
et
al
host
immun
respons
sar
may
first
map
detail
term
emerg
infecti
diseas
use
multiplex
beadbas
flow
cytometr
immunoassay
technolog
studi
host
respons
infecti
diseas
may
identifi
novel
host
respons
gene
diagnost
andor
prognost
acut
phase
diseas
model
host
gene
express
differ
subset
patient
onset
symptom
convalesc
multipl
genet
pathway
may
found
show
chang
express
pattern
prognost
capabl
vari
cours
diseas
role
interferon
interferon
respons
gene
play
regul
longlast
uncontrol
inflammatori
event
involv
sar
worth
care
examin
summari
multiplex
beadbas
flow
cytometr
immunoassay
emerg
power
tool
profil
natur
microbi
agent
biolog
sampl
host
respons
infecti
diseas
develop
new
fluoresc
dye
specif
highaffin
antibodi
highthroughput
multiparamet
method
flow
cytomet
beadbas
immunoassay
signific
impact
establish
prophylact
therapeut
measur
counter
acut
chronic
infecti
diseas
caus
microbi
pathogen
product
afford
userfriendli
equip
materi
peopl
develop
develop
countri
could
benefit
dramat
advanc
techniqu
diagnost
microbiolog
